BioNTech's Founder Era Ends: A New CEO Inherits a Halved Forecast and a Shrinking Footprint

BioNTech's Q2 revenue fell 59.5% to €105.6M, missing estimates, prompting a 2026 guidance cut. Founders' exit adds to investor concerns amid oncology pipeline hopes.

The numbers BioNTech posted for the second quarter were bad enough on their own. But the company chose the same week to announce that its founding duo is stepping aside — a double dose of news that has left investors weighing a crumbling COVID franchise against a leadership reset and a still-substantial oncology pipeline.

The share price has been drifting sideways through the turbulence. In Frankfurt on Friday, the stock closed at 79.90 euros, up 1.08 percent, after shedding ground in the preceding sessions. That leaves the equity roughly a quarter — 24.48 percent to be precise — below its January 52-week high, and 5.01 percent shy of its 200-day moving average. Across the Atlantic, the Nasdaq-listed ADS settled at 91.19 dollars on Thursday, down 1.07 percent on the day, with the German listing hovering around 79.05 euros — about 25 percent under the January peak of 105.80 euros. The weekly gain of 0.57 percent has done little to dent a broader downtrend that still leaves the stock more than six percent beneath its 200-day line of 84.11 euros.

A Revenue Collapse and a Slashed Outlook

The financial damage was laid bare in figures released between August 4 and 6. Second-quarter revenue tumbled 59.5 percent year-on-year to 105.6 million euros (the secondary report rounds this to 106 million euros, versus 261 million in the prior-year quarter), missing analyst expectations by roughly 32 percent. Management blamed fading demand for COVID-19 vaccines and delayed milestone payments from partnerships.

The shortfall forced a sharp downward revision to the full-year guidance. BioNTech now expects 2026 revenue of 1.6 to 1.9 billion euros, down from the previously communicated range of 2.0 to 2.3 billion. Research spending is also being trimmed: the company now plans to invest 2.0 to 2.3 billion euros in R&D this year, rather than the 2.2 to 2.5 billion originally budgeted.

The bottom line made for grim reading. The second quarter produced a net loss under IFRS of 820.8 million euros, compared with a loss of 190.4 million euros in the same period last year (the secondary source cites 821 million versus 387 million, reflecting a different comparative basis). Diluted loss per share came in at 3.24 euros. For the first half of 2026, the net loss widened to 1.35 billion euros — a 68 percent increase over the 824 million euros recorded in the first half of 2025.

The sell-side has scrambled to recalibrate. The statutory consensus for 2026 revenue has fallen to 1.86 billion euros from 2.17 billion, while the expected loss per share has been revised to 5.45 euros from 4.40 euros. Seventeen analysts contributed to the updated estimates. The average price target, however, has held steady at 121 dollars, albeit with a wide dispersion between 76.23 and 148 dollars — a sign that opinions on the company's trajectory are sharply divided.

A Changing of the Guard

The leadership transition was formalized on August 3, when the supervisory board named Guido Oelkers as the next CEO. Oelkers, currently at the helm of Swedish biopharma group Sobi, will take over no later than February 1, 2027, succeeding co-founder Ugur Sahin. His track record at Sobi includes the licensing of Synagis, the roughly 915-million-dollar acquisition of Dova, and the launch of Altuviiio. His stated ambition at BioNTech: multiple approved products by 2030.

Sahin and his wife, co-founder Özlem Türeci, have confirmed they will relinquish their executive board roles by the end of 2026 to build a new, independent mRNA innovation venture. BioNTech will retain a minority stake in the spin-off and will transfer certain mRNA technology rights to the new entity. For long-term shareholders, the departure marks the end of an era — the company's identity has been inseparable from its founders since the Pfizer-partnered COVID vaccine made it a household name.

The handover comes at a delicate operational moment. BioNTech is simultaneously contracting its manufacturing footprint: sites in Idar-Oberstein, Marburg and Tübingen are slated to close by the end of 2027, with the Singapore facility following in the first quarter of that year. The capacity cuts underscore how aggressively the company must adapt its cost base to a post-pandemic reality.

Buybacks, Insider Sales, and a Pipeline in Focus

Despite the red ink, BioNTech has not wavered on capital returns. During the second quarter, it repurchased 1,693,056 ADSs for 151.6 million dollars (approximately 131.8 million euros) under a buyback program with a total volume of one billion dollars.

Elsewhere, an April insider transaction drew attention: COO Sierk Poetting sold shares worth roughly 5.5 million dollars through his vehicle Tofino GmbH under a pre-arranged trading plan, reducing his indirect stake by 11 percent.

The strategic narrative now rests on the oncology pipeline. BioNTech is running 14 pivotal clinical trials in this area, including five for the PD-L1/VEGF candidate Pumitamig (BNT327) and one for the antibody-drug conjugate Elfetabart Drozuntecan. In vaccines, the European Commission granted approval in July for an XFG-variant-adapted COVID-19 shot developed with Pfizer for the 2026/2027 season.

Analyst reactions to the guidance cut have been measured. Citigroup trimmed its price target to 125 dollars from 130 on August 5, keeping a Buy rating. Jefferies followed on August 4, lowering its target to 138 dollars from 151, citing the disappointing quarter while pointing to potential operational improvements under the new leadership — also maintaining a Buy recommendation.

The picture that emerges is of a company in transition on every front: revenue, leadership, and physical footprint. Whether the new chief executive can restore investor confidence will likely define BioNTech's trajectory through the coming quarters.